Methods of use growth factors for treating heart disease
OwnerWayne P. Francoinventor
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.
Claims15
A method for the systematic multi-tiered treatment of heart disease by delivery of therapeutic growth factor proteins comprising the steps of:
- a.) selecting a patient displaying symptoms of heart disease;
- b.) administering at least one dose of an effective amount of a first therapeutic growth factor protein formulation by oral inhalation;
- c.) monitoring levels of CPK-MB in the patient;
- d.) determining whether administration of the growth factor protein formulation was effective in treating the symptoms of heart disease in the patient;
- e.) administering one or more additional doses of a second growth factor protein formulation by a method of delivery more invasive than delivery by oral inhalation;
- and
- f.) repeating steps c.) through e.) until there is a clinical indication of amelioration of the symptoms of heart disease in the patient, or until there is a contraindication to continued treatment.
A method for the administration of therapeutic amounts of a growth factor protein formulation in the treatment of heart disease comprising the step of delivering the protein formulation by inhalation therapy.
A method for monitoring clinical effectiveness of administration of a growth factor protein formulation in the treatment of heart disease, the method comprising the steps of:
- a.) obtaining a sample of a biological fluid from a patient displaying symptoms of heart disease;
- b.) performing an assay of the biological fluid to determine an amount of CPK-MB present in the fluid;
- c.) administering a therapeutic amount of a growth factor protein formulation to the patient;
- and
- d.) repeating steps b.) and c.) until the assayed amount of CPK-MB in the biological fluid has decreased by an amount sufficient to indicate the clinical effectiveness of the administration of the growth factor protein formulation.
Dependencies are inferred from the claim text.